Rigel Pharmaceuticals Inc RIGL:NASDAQ

Last Price$1.25NASDAQ Closing Price as of 4:00PM ET 7/01/22

Today's Change+0.12(10.62%)
Bid (Size)$1.17 (9)
Ask (Size)$1.20 (21)
Day Low / High$1.11 - 1.29
Volume5.0 M
 

View Biotechnology IndustryPeer Comparison as of 07/01/2022

 

Rigel Pharmaceuticals Inc ( NASDAQ )

Price: $1.25
Change: +0.12 (10.62%)
Volume: 5.0 M
4:00PM ET 7/01/2022
 
 

CEL-SCI Corp ( NYSE MKT LLC )

Price: $4.10
Change: -0.40 (8.89%)
Volume: 414.5 K
8:00PM ET 7/01/2022
 
 

Co-Diagnostics Inc ( NASDAQ )

Price: $5.84
Change: +0.23 (4.10%)
Volume: 455.3 K
4:00PM ET 7/01/2022
 
 

Selecta Biosciences Inc ( NASDAQ )

Price: $1.33
Change: +0.02 (1.53%)
Volume: 1.8 M
4:00PM ET 7/01/2022
 
 

VistaGen Therapeutics Inc ( NASDAQ )

Price: $0.87
Change: -0.008 (0.90%)
Volume: 903.5 K
4:00PM ET 7/01/2022
 

Read more news Recent News

Insider Buy: Rigel Pharmaceuticals
5:20PM ET 6/13/2022 MT Newswires

Raul R Rodriguez, Director, CEO, President, on June 09, 2022, executed a purchase for 1,000,000 shares in Rigel Pharmaceuticals (RIGL) for $688,400....

BMO Lowers Rigel Pharmaceuticals' Price Target to $3 From $7, Maintains Outperform Rating
10:37AM ET 6/09/2022 MT Newswires

Rigel Pharmaceuticals (RIGL) has an average rating of outperform and price targets ranging from $1 to $7, according to analysts polled by Capital IQ. (MT...

B. Riley Lowers Rigel Pharmaceuticals' Price Target to $1.25 from $4 After Disappointing Trial Data on Fostamatinib, Keeps Neutral Rating
8:53AM ET 6/09/2022 MT Newswires

B. Riley lowered Rigel Pharmaceuticals' (RIGL) price target to $1.25 from $4 after the company announced Wednesday that its top-line efficacy and safety...

--Citigroup Downgrades Rigel Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $0.80 From $7
7:18AM ET 6/09/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionRigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA. View company web site for more details
Address1180 Veterans Boulevard
South San Francisco, California 94080-1985
Phone+1.650.624.1100
Number of Employees158
Recent SEC Filing06/23/20228-K
President, Chief Executive Officer & DirectorRaul R. Rodriguez
Chief Financial Officer & Executive Vice PresidentDean L. Schorno
Chief Medical Officer & Executive Vice PresidentWolfgang Dummer
Chief Commercial Officer & Executive VPDavid Santos

Company Highlights

Price Open$1.12
Previous Close$1.13
52 Week Range$0.64 - 4.55
Market Capitalization$215.1 M
Shares Outstanding172.1 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/02/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.48
Beta vs. S&P 500N/A
Revenue$44.5 M
Net Profit Margin-99.89%
Return on Equity-219.06%

Analyst Ratings as of 06/08/2022

Buy
2
Overweight
0
Hold
5
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset